Post-selec modification methods
First Claim
Patent Images
1. A method comprising modifying a first aptamer that is capable of binding a target protein whereby the first aptamer comprises a first modified C-5 position uracil, and wherein the modification to the first aptamer results in a second aptamer having improved binding affinity for the target protein compared to the binding affinity of the first aptamer for the target protein;
- wherein the modification to the first aptamer is a substitution of the first modified C-5 position uracil with a second modified C-5 position uracil, wherein the first modified C-5 position uracil and the second modified C-5 position uracil are different C-5 position modified uracils, and wherein the first modified C-5 position uracil has a hydrophobic moiety selected from the group consisting of;
3 Assignments
0 Petitions
Accused Products
Abstract
Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.
-
Citations
6 Claims
-
1. A method comprising modifying a first aptamer that is capable of binding a target protein whereby the first aptamer comprises a first modified C-5 position uracil, and wherein the modification to the first aptamer results in a second aptamer having improved binding affinity for the target protein compared to the binding affinity of the first aptamer for the target protein;
- wherein the modification to the first aptamer is a substitution of the first modified C-5 position uracil with a second modified C-5 position uracil, wherein the first modified C-5 position uracil and the second modified C-5 position uracil are different C-5 position modified uracils, and wherein the first modified C-5 position uracil has a hydrophobic moiety selected from the group consisting of;
- View Dependent Claims (2, 3, 4, 5, 6)
- wherein the modification to the first aptamer is a substitution of the first modified C-5 position uracil with a second modified C-5 position uracil, wherein the first modified C-5 position uracil and the second modified C-5 position uracil are different C-5 position modified uracils, and wherein the first modified C-5 position uracil has a hydrophobic moiety selected from the group consisting of;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeSomaLogic Operating Co., Inc. (Somalogic Incorporated)
-
Original AssigneeSomalogic Incorporated
-
InventorsJarvis, Thale C., Rohloff, John C., Gelinas, Amy D., Zhang, Chi, Drolet, Daniel W., Waugh, Sheela M., Janjic, Nebojsa
-
Primary Examiner(s)Vivlemore, Tracy
-
Application NumberUS15/602,377Publication NumberTime in Patent Office651 DaysField of SearchNoneUS Class CurrentCPC Class CodesA61P 11/00 Drugs for disorders of the ...A61P 13/12 of the kidneysA61P 19/04 for non-specific disorders ...A61P 27/02 Ophthalmic agentsA61P 27/04 Artificial tears; Irrigatio...A61P 27/06 Antiglaucoma agents or mioticsA61P 27/12 for cataractsA61P 35/00 Antineoplastic agentsA61P 35/02 specific for leukemiaA61P 43/00 Drugs for specific purposes...A61P 9/00 Drugs for disorders of the ...A61P 9/10 for treating ischaemic or a...A61P 9/12 AntihypertensivesC12N 15/115 Aptamers, i.e. nucleic acid...C12N 2310/16 AptamersC12N 2310/315 PhosphorothioatesC12N 2310/318 where the PO2 is completely...C12N 2310/321 2'-O-R ModificationC12N 2310/322 2'-R ModificationC12N 2310/335 Modified T or UView All
